Closing Strong: Tandem Diabetes Care Inc (TNDM) Ends at 42.15, Down -4.20 from Last Close

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

After finishing at $44.00 in the prior trading day, Tandem Diabetes Care Inc (NASDAQ: TNDM) closed at $42.15, down -4.20%. In other words, the price has decreased by -$4.20 from its previous closing price. On the day, 1.66 million shares were traded. TNDM stock price reached its highest trading level at $44.105 during the session, while it also had its lowest trading level at $41.8.

Ratios:

Our goal is to gain a better understanding of TNDM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.01 and its Current Ratio is at 3.81. In the meantime, Its Debt-to-Equity ratio is 1.96 whereas as Long-Term Debt/Eq ratio is at 1.89.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on April 29, 2024, Upgraded its rating to Overweight and sets its target price to $45 from $21 previously.

On April 25, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $34 to $45.

Stifel Upgraded its Hold to Buy on March 26, 2024, whereas the target price for the stock was revised from $24 to $37.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 27 ’23 when Allen Dick bought 5,000 shares for $18.96 per share. The transaction valued at 94,778 led to the insider holds 19,962 shares of the business.

Vosseller Leigh bought 6,200 shares of TNDM for $95,395 on Nov 08 ’23. The EVP & CHIEF FINANCIAL OFFICER now owns 11,860 shares after completing the transaction at $15.39 per share. On Nov 08 ’23, another insider, Hansen Shannon Marie, who serves as the Chief Legal Officer of the company, bought 1,935 shares for $15.44 each. As a result, the insider paid 29,884 and bolstered with 1,935 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNDM now has a Market Capitalization of 2722447616 and an Enterprise Value of 2851677696. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.54 while its Price-to-Book (P/B) ratio in mrq is 11.20. Its current Enterprise Value per Revenue stands at 3.703 whereas that against EBITDA is -21.816.

Stock Price History:

The Beta on a monthly basis for TNDM is 1.22, which has changed by 0.32092464 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, TNDM has reached a high of $47.00, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is 28.69%, while the 200-Day Moving Average is calculated to be 61.39%.

Shares Statistics:

The stock has traded on average 1.90M shares per day over the past 3-months and 1942480 shares per day over the last 10 days, according to various share statistics. A total of 65.55M shares are outstanding, with a floating share count of 64.15M. Insiders hold about 0.67% of the company’s shares, while institutions hold 112.83% stake in the company. Shares short for TNDM as of 1713139200 were 9244776 with a Short Ratio of 4.87, compared to 1710460800 on 8077670. Therefore, it implies a Short% of Shares Outstanding of 9244776 and a Short% of Float of 22.37.

Earnings Estimates

The current rating of Tandem Diabetes Care Inc (TNDM) is the result of assessments by 11.0 analysts actively engaged in evaluating its market dynamics.On average, analysts expect EPS of -$0.54 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.61, while EPS last year was -$0.3. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.22 and low estimates of -$0.4.

Analysts are recommending an EPS of between -$1.47 and -$1.74 for the fiscal current year, implying an average EPS of -$1.64. EPS for the following year is -$1.1, with 12.0 analysts recommending between -$0.76 and -$1.39.

Revenue Estimates

14 analysts predict $205.63M in revenue for the current quarter. It ranges from a high estimate of $210.28M to a low estimate of $203.2M. As of the current estimate, Tandem Diabetes Care Inc’s year-ago sales were $197.36MFor the next quarter, 14 analysts are estimating revenue of $220.53M. There is a high estimate of $225.1M for the next quarter, whereas the lowest estimate is $214M.

A total of 17 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $874.45M, while the lowest revenue estimate was $866.22M, resulting in an average revenue estimate of $869.05M. In the same quarter a year ago, actual revenue was $747.72MBased on 16 analysts’ estimates, the company’s revenue will be $968.65M in the next fiscal year. The high estimate is $1.08B and the low estimate is $938M.

Most Popular

[the_ad id="945"]